Arcus Q1 net loss $128M, cash $876M; discontinues Phase 3 STAR-121 in NSCLC

Arcus Biosciences, Inc.

2026-Q1 EPS reported -$1.02 revenue$17,000,000

Net loss $128M for Q1 2026 vs $112M Q1 2025; revenue $17M down from $28M.
Cash $876M at Mar 31, 2026, down from $1.0B at Dec 31, 2025; expect ~$600M year-end, runway to H2 2028.
Discontinued Phase 3 STAR-121 (domvanalimab) in NSCLC after futility analysis (OS not improved vs pembrolizumab+chemo).
Pipeline: casdatifan Phase 3 PEAK-1 enrolling; 1L Phase 3 initiation expected year-end; new I&I candidate AB102 entering clinic Q3 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arcus Biosciences, Inc. reported financial results for three months ended March 31, 2026.

Period: three months ended March 31, 2026
Result: reported results

Exact text from the filing

On May 5, 2026 , Arcus Biosciences, Inc. issued a press release announcing its financial results for the three months ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Arcus Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001724521-26-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.